EQT Leads Investment in Mosanna to Advance Nasal Spray Therapy for Sleep Apnea Patients

EQT Leads Investment in Mosanna to Advance Nasal Spray Therapy for Sleep Apnea Patients

(IN BRIEF) EQT Life Sciences has led a Series A investment in Mosanna Therapeutics to advance its lead drug candidate, MOS118—a nasal spray designed to treat obstructive sleep apnea—into Phase 2 trials. Co-investors include Pivotal bioVenture Partners, Forbion, Norwest, and others. With nearly a billion people affected by OSA globally, MOS118 offers a non-invasive pharmaceutical alternative to mechanical therapies. Alongside the funding, Mosanna has appointed Dr. David Weber as CEO to steer the company through clinical development and strategic growth.

(PRESS RELEASE) STOCKHOLM, 10-Jun-2025 — /EuropaWire/ — EQT Life Sciences has announced a significant Series A investment through its LSP 7 fund in Mosanna Therapeutics, a Basel-based clinical-stage biotechnology company developing an innovative nasal spray therapy for obstructive sleep apnea (OSA). The funding round, co-led by Pivotal bioVenture Partners along with Forbion, Broadview Ventures, and Norwest, will be used to progress Mosanna’s lead candidate MOS118 into Phase 2 clinical development and support pipeline expansion. Existing investors, including founding investor Forty51 Ventures, Supermoon Capital, and High-Tech Gründerfonds (HTGF), also participated.

Mosanna’s approach redefines OSA treatment by addressing it as a neurological and muscular disorder, rather than a purely mechanical one. MOS118, the company’s flagship therapy, is a nighttime nasal spray designed to restore the body’s natural airway reflex during sleep by targeting the upper airway muscles responsible for keeping the airway open. This contrasts with the current standard of care, which often involves uncomfortable and invasive mechanical devices such as CPAP machines.

Dr. Daniela Begolo, Managing Director at EQT Life Sciences, who will also join Mosanna’s Board of Directors, stated: “MOS118 has the potential to transform how we manage sleep apnea. Its novel mechanism of restoring natural reflexes, combined with the ease of a nasal spray, addresses the long-standing challenge of patient adherence and therapeutic effectiveness.”

Obstructive sleep apnea is a widespread health issue, affecting nearly 1 billion individuals globally. Untreated OSA is linked to several serious conditions, including cardiovascular disease, stroke, and daytime fatigue, yet many patients remain undiagnosed or poorly served by current therapies.

To lead the company through its next growth phase, Mosanna has appointed biotech veteran Dr. David Weber as President and CEO. Dr. Weber brings over three decades of experience in drug development, strategic leadership, and capital formation. His appointment is expected to bolster Mosanna’s clinical execution and market positioning. He also joins the company’s Board of Directors.

“Mosanna is pioneering a non-invasive treatment that aligns with how the body naturally keeps airways open when awake,” said Dr. Weber. “Our goal is to replicate that biological reflex during sleep through a simple, effective nasal spray. This funding propels us toward offering a much-needed alternative for patients who struggle with traditional OSA therapies.”

With operations in Redwood City, California, and Basel, Switzerland, Mosanna is well-positioned to deliver an impactful treatment that could dramatically improve the quality of life for millions living with sleep apnea.

For additional information, visit www.mosanna.com or contact press@eqtpartners.com.

Media Contact:

EQT Press Office, press@eqtpartners.com

SOURCE: EQT AB